Empowered Patient Podcast

Dr. David Carmouche, Chief Clinical Transformation Officer at Lumeris, is addressing the primary care shortage by providing a platform that supports primary care physicians in managing a broader patient population and delivering better health outcomes. The Lumeris platform, Tom, is an AI-powered virtual assistant that can interact with patients, provide chronic disease management, education and support, and coordinate care on behalf of providers. Tom can improve efficiency, reduce clinician burnout, and provide more convenient and personalized experiences for patients.  David explains, "And so, they built the company, Lumeris, as a commercialization arm of their relationship to empower other primary care physicians to manage populations and deliver better health outcomes at a lower cost. And so for the last 12 years or so, Lumaris has been partnering largely with large medical groups and health systems to help them manage populations, Medicare, Medicaid, and commercial populations, and helping drive high performance and high outcomes within those relationships. The economics are shared economics, so when the plans and providers are successful by delivering better outcomes, Lumeris shares in those rewards."  "Given the 20-year history that I mentioned of understanding care deeply as a provider of care and as a partner to those providers of care, we have the fortune to build new technology to support primary care. Our environment starts with aggregating data, and that data helps us define a view of a patient. That data could come from an electronic medical record, it could come from claims data from a pharmacist, it could come from claims data from a payer, or it could come from a pharmacist or a lab. It could be consumer data that is purchasable, as organizations like Target, Walmart, and others use to market to us today. We aggregate that data to create a 360° view of a patient. Then we're able to leverage some of the new artificial intelligence that creates the ability for the platform to interact with patients on behalf of their clinical care teams at points in time where we understand that there is a defined next best clinical action that might help you in your health journey." #Lumeris #MedAI #DigitalHealth #PrimaryCareProviders lumeris.com Listen to the podcast here

Dr. David Carmouche, Chief Clinical Transformation Officer at Lumeris, is addressing the primary care shortage by providing a platform that supports primary care physicians in managing a broader patient population and delivering better health outcomes. The Lumeris platform, Tom, is an AI-powered virtual assistant that can interact with patients, provide chronic disease management, education and support, and coordinate care on behalf of providers. Tom can improve efficiency, reduce clinician burnout, and provide more convenient and personalized experiences for patients.  David explains, "And so, they built the company, Lumeris, as a commercialization arm of their relationship to empower other primary care physicians to manage populations and deliver better health outcomes at a lower cost. And so for the last 12 years or so, Lumaris has been partnering largely with large medical groups and health systems to help them manage populations, Medicare, Medicaid, and commercial populations, and helping drive high performance and high outcomes within those relationships. The economics are shared economics, so when the plans and providers are successful by delivering better outcomes, Lumeris shares in those rewards."  "Given the 20-year history that I mentioned of understanding care deeply as a provider of care and as a partner to those providers of care, we have the fortune to build new technology to support primary care. Our environment starts with aggregating data, and that data helps us define a view of a patient. That data could come from an electronic medical record, it could come from claims data from a pharmacist, it could come from claims data from a payer, or it could come from a pharmacist or a lab. It could be consumer data that is purchasable, as organizations like Target, Walmart, and others use to market to us today. We aggregate that data to create a 360° view of a patient. Then we're able to leverage some of the new artificial intelligence that creates the ability for the platform to interact with patients on behalf of their clinical care teams at points in time where we understand that there is a defined next best clinical action that might help you in your health journey." #Lumeris #MedAI #DigitalHealth #PrimaryCareProviders lumeris.com Download the transcript here

Jeff Bennett, Chief Strategy and Innovation Officer at Modivcare, is addressing and expanding supportive care services to provide transportation, personal care services, and remote patient monitoring. A lack of transportation leads to missed appointments and therapies, necessitating a coordinated approach to support vulnerable populations. Modivcare utilizes remote sensors and AI to enhance human engagement and coordination, and is designed to be both preventative and predictive, keeping patients healthy and out of the hospital.  Jeff explains, "Modivcare works on behalf of health plans, states, and risk-based entities. We provide supportive care services that meet the needs and address the needs of patients. One of those services is transportation, so non-emergency medical transportation. We also provide personal care services, which support members with activities of daily living, like bathing, meal preparation, and such. And then finally, I lead the monitoring organization, which provides services to monitor members or patients at home so they can live and age at home on their own." "The biggest need, at the top, is that our members have health-related social needs or SDOH needs. They also are living with chronic conditions, so they need supportive care services that not only provides that core service -- so there's the obvious "I need a ride" or "if I press the button because I've fallen and I need 911 to be called if I need an ambulance or my caregiver or family member to come help me." But most importantly, the services that they need are providing an engagement service. Really, what we provide is a supportive care service that drives human connection through cutting-edge technology that drives continuous engagement. They always know that we're here, and we listen to them. We understand their needs and try to address those needs, which could be healthcare-related, social-related, or simply loneliness. So it spans that broad spectrum. And any one of our services, we're delivering that core service, but we're also driving engagement and listening for what else the member needs." #Modivcare #SDOH #SupportiveCareServices #MedAI #DigitalHealth #CareCoordination modivcare.com Listen to the podcast here

Jeff Bennett, Chief Strategy and Innovation Officer at Modivcare, is addressing and expanding supportive care services to provide transportation, personal care services, and remote patient monitoring. A lack of transportation leads to missed appointments and therapies, necessitating a coordinated approach to support vulnerable populations. Modivcare utilizes remote sensors and AI to enhance human engagement and coordination, and is designed to be both preventative and predictive, keeping patients healthy and out of the hospital.  Jeff explains, "Modivcare works on behalf of health plans, states, and risk-based entities. We provide supportive care services that meet the needs and address the needs of patients. One of those services is transportation, so non-emergency medical transportation. We also provide personal care services, which support members with activities of daily living, like bathing, meal preparation, and such. And then finally, I lead the monitoring organization, which provides services to monitor members or patients at home so they can live and age at home on their own." "The biggest need, at the top, is that our members have health-related social needs or SDOH needs. They also are living with chronic conditions, so they need supportive care services that not only provides that core service -- so there's the obvious "I need a ride" or "if I press the button because I've fallen and I need 911 to be called if I need an ambulance or my caregiver or family member to come help me." But most importantly, the services that they need are providing an engagement service. Really, what we provide is a supportive care service that drives human connection through cutting-edge technology that drives continuous engagement. They always know that we're here, and we listen to them. We understand their needs and try to address those needs, which could be healthcare-related, social-related, or simply loneliness. So it spans that broad spectrum. And any one of our services, we're delivering that core service, but we're also driving engagement and listening for what else the member needs." #Modivcare #SDOH #SupportiveCareServices #MedAI #DigitalHealth #CareCoordination modivcare.com Download the transcript here

Peter Ordentlich, Chief Scientific Officer and Founder at Syndax Pharmaceuticals, a clinical oncology company, is focused on developing precision medicine approaches to treat cancer and chronic graft-versus-host disease. The menin protein plays a critical role in driving certain types of blood cancers, and the Synex therapy is a menin inhibitor that can disrupt this cancer-driving pathway. The platform is also developing an antibody addressing the unmet needs in cGVHD to reduce the disease-driving macrophages. Peter explains, "Syndax is a clinical oncology company, which means we're focused primarily on cancer, and we're primarily doing clinical development. We started the company really looking at resistance pathways to developing cancer, and we've been focused on two main areas. One in the indication space of leukemia, which are certain types of blood cancers, and that's with a program we have around the small molecule drug called revumenib. We are also focused in another area of diseases called chronic graft-versus-host disease. These are diseases that happen post-stem cell transplant, and there we're developing an antibody called axatilimab. And so those two programs are really what we've been focusing on for the last five or six years and have led to each of those drugs." "So menin is a very interesting protein, and basically what this is, it's called a scaffold protein. And you can imagine a scaffold, just something you build things upon. And so menin interacts with DNA through a variety of other factors, and you build on top of this a complex of other proteins that can turn genes on and off. And in the case of certain types of leukemias, the mutation that creates certain other cancer-causing proteins binds to menin. That's what drives certain genes that drive leukemia to always be turned on. And so what we've tried to do and others have tried to do is disrupt that interaction and essentially cause the scaffold to fall apart. And when that falls apart, you can no longer keep those genes on that drive leukemia, and instead, you have genes that essentially cause the cell to stop growing."  #SyndaxPharma #AcuteLeukemia #cGHVD #Oncology #PrecisionMedicine #Menin #MeninInhibitors syndax.com Listen to the podcast here

Peter Ordentlich, Chief Scientific Officer and Founder at Syndax Pharmaceuticals, a clinical oncology company, is focused on developing precision medicine approaches to treat cancer and chronic graft-versus-host disease. The menin protein plays a critical role in driving certain types of blood cancers, and the Synex therapy is a menin inhibitor that can disrupt this cancer-driving pathway. The platform is also developing an antibody addressing the unmet needs in cGVHD to reduce the disease-driving macrophages. Peter explains, "Syndax is a clinical oncology company, which means we're focused primarily on cancer, and we're primarily doing clinical development. We started the company really looking at resistance pathways to developing cancer, and we've been focused on two main areas. One in the indication space of leukemia, which are certain types of blood cancers, and that's with a program we have around the small molecule drug called revumenib. We are also focused in another area of diseases called chronic graft-versus-host disease. These are diseases that happen post-stem cell transplant, and there we're developing an antibody called axatilimab. And so those two programs are really what we've been focusing on for the last five or six years and have led to each of those drugs." "So menin is a very interesting protein, and basically what this is, it's called a scaffold protein. And you can imagine a scaffold, just something you build things upon. And so menin interacts with DNA through a variety of other factors, and you build on top of this a complex of other proteins that can turn genes on and off. And in the case of certain types of leukemias, the mutation that creates certain other cancer-causing proteins binds to menin. That's what drives certain genes that drive leukemia to always be turned on. And so what we've tried to do and others have tried to do is disrupt that interaction and essentially cause the scaffold to fall apart. And when that falls apart, you can no longer keep those genes on that drive leukemia, and instead, you have genes that essentially cause the cell to stop growing."  #SyndaxPharma #AcuteLeukemia #cGHVD #Oncology #PrecisionMedicine #Menin #MeninInhibitors syndax.com Download the transcript here

Vikram Bhaskran, CEO and Co-Founder, and Dr. Rohan Ramakrishna, Chief Medical Officer and Co-Founder of Roon, have taken on the mission to provide trustworthy and personalized medical information to patients and caregivers. Leveraging technology and the expertise of medical professionals, Roon has created a comprehensive resource for navigating medical challenges. They emphasize the importance of addressing misinformation and providing accurate, science-based information. The platform is not intended to replace doctors, but to supplement relevant information and enable better communication with healthcare providers and improve patient outcomes. Vikram explains, "Our mission is to be the best place online for anyone navigating any health condition. I started the company really through my own journey as a caregiver to my dad, who had ALS. And in that journey, I had two insights. One is that the biggest tech companies fail us. And in this moment of crisis, most people navigating any health condition will turn to "Doctor Google" and Facebook groups, which can be an overwhelming experience. And so I felt we could do better as someone coming from the tech world. I was at Pinterest before this, and my second insight was that there's a finite number of doctors. And so the experience of health today for really anyone is that you spend a ton of time in waiting rooms. You spend a ton of time waiting for someone to answer your health questions. And so Roon was born out of those two insights. And our goal is to be the best online platform to scale the world's best medical experts and their knowledge." Rohan elaborates, "The doctors are from more than 70 different academic medical institutions, and the number is growing. They represent all the experts who have expertise to share alongside the health journeys we've launched. So as of today, we've launched brain cancer, ALS, dementia, Fertility and Family Building, PCOS, endometriosis, menopause, and we are soon to launch several other conditions related to women's health, including gynecological health. Our experts span the doctors you would expect, such as oncologists, neurologists, and OBGYNs, among others, but also social workers, physical therapists, occupational therapists, speech therapists, and legal and financial counselors - really anyone who has real expertise that they can lend to the experience of a journey. So much of dementia care, for example, is not driven by your neurologist, but by the experience of caring for someone who needs help, whether it's at a memory care facility or a skilled nursing facility, dealing with issues that doctors typically don't have a great answer for."  #Roon #HealthcareInformation #MedAI #HealthcareOutcomes #DigitalHealth roon.com Listen to the podcast here

Vikram Bhaskran, CEO and Co-Founder, and Dr. Rohan Ramakrishna, Chief Medical Officer and Co-Founder of Roon, have taken on the mission to provide trustworthy and personalized medical information to patients and caregivers. Leveraging technology and the expertise of medical professionals, Roon has created a comprehensive resource for navigating medical challenges. They emphasize the importance of addressing misinformation and providing accurate, science-based information. The platform is not intended to replace doctors, but to supplement relevant information and enable better communication with healthcare providers and improve patient outcomes. Vikram explains, "Our mission is to be the best place online for anyone navigating any health condition. I started the company really through my own journey as a caregiver to my dad, who had ALS. And in that journey, I had two insights. One is that the biggest tech companies fail us. And in this moment of crisis, most people navigating any health condition will turn to "Doctor Google" and Facebook groups, which can be an overwhelming experience. And so I felt we could do better as someone coming from the tech world. I was at Pinterest before this, and my second insight was that there's a finite number of doctors. And so the experience of health today for really anyone is that you spend a ton of time in waiting rooms. You spend a ton of time waiting for someone to answer your health questions. And so Roon was born out of those two insights. And our goal is to be the best online platform to scale the world's best medical experts and their knowledge." Rohan elaborates, "The doctors are from more than 70 different academic medical institutions, and the number is growing. They represent all the experts who have expertise to share alongside the health journeys we've launched. So as of today, we've launched brain cancer, ALS, dementia, Fertility and Family Building, PCOS, endometriosis, menopause, and we are soon to launch several other conditions related to women's health, including gynecological health. Our experts span the doctors you would expect, such as oncologists, neurologists, and OBGYNs, among others, but also social workers, physical therapists, occupational therapists, speech therapists, and legal and financial counselors - really anyone who has real expertise that they can lend to the experience of a journey. So much of dementia care, for example, is not driven by your neurologist, but by the experience of caring for someone who needs help, whether it's at a memory care facility or a skilled nursing facility, dealing with issues that doctors typically don't have a great answer for."  #Roon #HealthcareInformation #MedAI #HealthcareOutcomes #DigitalHealth roon.com Download the transcript here

Barry Quart, CEO of Connect Biopharma, is developing the next generation of monoclonal antibodies targeting inflammatory respiratory diseases such as COPD and asthma. Administered subcutaneously, their lead program targets IL-4 and has demonstrated the ability to rapidly improve airway function and reduce the incidence of acute exacerbations in these patients. Current treatments rely on steroids and bronchodilators, which do not address the underlying inflammatory causes, an area that has largely been under-addressed by other biologic developers. Barry explains, "Connect has been dedicated for quite a few years to designing next-generation monoclonal antibodies targeting inflammatory diseases. I joined the company last year and really kind of turned the ship towards a sole focus on our lead program, which is rademikibart, a second-generation Dupixent, a monoclonal antibody targeting IL-4, a really important target for certain inflammatory diseases." "IL-4 can be used as a monoclonal antibody targeting IL-4 for diseases such as atopic dermatitis, asthma, and COPD, as well as several other conditions. We're focused on asthma and COPD. So, inflammatory respiratory disease, because our product has some unique characteristics that are going to allow us to focus on an area that's really been completely ignored by other developers of biologics in the respiratory space, and specifically on patients having acute exacerbations."  #ConnectBiopharma #MonoclonalAntibody #IL4 #COPD #Asthma #AtopicDermatitis #InflammatoryDiseases #RespiratoryDiseases connectbiopharm.com Listen to the podcast here

Barry Quart, CEO of Connect Biopharma, is developing the next generation of monoclonal antibodies targeting inflammatory respiratory diseases such as COPD and asthma. Administered subcutaneously, their lead program targets IL-4 and has demonstrated the ability to rapidly improve airway function and reduce the incidence of acute exacerbations in these patients. Current treatments rely on steroids and bronchodilators, which do not address the underlying inflammatory causes, an area that has largely been under-addressed by other biologic developers. Barry explains, "Connect has been dedicated for quite a few years to designing next-generation monoclonal antibodies targeting inflammatory diseases. I joined the company last year and really kind of turned the ship towards a sole focus on our lead program, which is rademikibart, a second-generation Dupixent, a monoclonal antibody targeting IL-4, a really important target for certain inflammatory diseases." "IL-4 can be used as a monoclonal antibody targeting IL-4 for diseases such as atopic dermatitis, asthma, and COPD, as well as several other conditions. We're focused on asthma and COPD. So, inflammatory respiratory disease, because our product has some unique characteristics that are going to allow us to focus on an area that's really been completely ignored by other developers of biologics in the respiratory space, and specifically on patients having acute exacerbations."  #ConnectBiopharma #MonoclonalAntibody #IL4 #COPD #Asthma #AtopicDermatitis #InflammatoryDiseases #RespiratoryDiseases connectbiopharm.com Download the transcript here

Dr. Kilian Kelly, Chief Executive Officer and Managing Director of Cynata Therapeutics, has taken on the challenge of manufacturing stem cell therapies consistently and at scale in order to drive the advancements necessary for the next generation of regenerative medicine. Cynata is employing a novel approach that utilizes a single source of pluripotent stem cells (iPSCs) and mesenchymal cell ancestors (MCAs) to generate mesenchymal stem cells (MSCs). Lead programs are targeting graft-versus-host disease, osteoarthritis, and diabetic wounds, where clinical trials have shown great promise to treat these and other diseases. Kilian explains, "We're a stem cell regenerative medicine company, and what we're trying to do is to change the way that we can manufacture stem cell therapies in a consistent and scalable way. I'm sure many of your listeners have heard about stem cell therapies of various types. The particular type of cells that we're working on are called mesenchymal stem cells or MSCs. They've shown lots of promise for lots of different purposes, but a real challenge has been making these cells consistently, especially when you try to do that at a large scale. We have a unique novel manufacturing platform, which helps us to address that major challenge." "The way that these cells were historically produced and indeed still are produced in most cases is by harvesting cells from, for example, somebody donating bone marrow or adipose tissue, also known as fat. And those approaches have certainly allowed a lot of early-stage clinical trials to be performed, which showed lots of really exciting results. But often what happens is that when you move to a larger scale using such a process, and you try to make much larger quantities of cells, perhaps using many different donors, you start to see a lot of inconsistency. There are a few reasons for this. When you have inconsistency with a product, it's inevitable that you're going to get inconsistent results." "If you have inconsistent results in a clinical trial, it becomes a bit of a lottery, and sometimes you can have very disappointing results that are hard to explain. So we think that's been a really big issue that has caused a lot of problems in the field. And aside from the impact on clinical trial results, we also need to think about the future when these products are available and on the market, and how you can actually, in practical terms, produce enough of these products. So, in a nutshell, I think that is probably the major challenge that the field has faced."  #CynataTherapeutics #StemCellTherapy #RegenerativeMedicine #iPSCs #MSCs #MCAs Cynata.com Listen to the podcast here  

Dr. Kilian Kelly, Chief Executive Officer and Managing Director of Cynata Therapeutics, has taken on the challenge of manufacturing stem cell therapies consistently and at scale in order to drive the advancements necessary for the next generation of regenerative medicine. Cynata is employing a novel approach that utilizes a single source of pluripotent stem cells (iPSCs) and mesenchymal cell ancestors (MCAs) to generate mesenchymal stem cells (MSCs). Lead programs are targeting graft-versus-host disease, osteoarthritis, and diabetic wounds, where clinical trials have shown great promise to treat these and other diseases. Kilian explains, "We're a stem cell regenerative medicine company, and what we're trying to do is to change the way that we can manufacture stem cell therapies in a consistent and scalable way. I'm sure many of your listeners have heard about stem cell therapies of various types. The particular type of cells that we're working on are called mesenchymal stem cells or MSCs. They've shown lots of promise for lots of different purposes, but a real challenge has been making these cells consistently, especially when you try to do that at a large scale. We have a unique novel manufacturing platform, which helps us to address that major challenge." "The way that these cells were historically produced and indeed still are produced in most cases is by harvesting cells from, for example, somebody donating bone marrow or adipose tissue, also known as fat. And those approaches have certainly allowed a lot of early-stage clinical trials to be performed, which showed lots of really exciting results. But often what happens is that when you move to a larger scale using such a process, and you try to make much larger quantities of cells, perhaps using many different donors, you start to see a lot of inconsistency. There are a few reasons for this. When you have inconsistency with a product, it's inevitable that you're going to get inconsistent results." "If you have inconsistent results in a clinical trial, it becomes a bit of a lottery, and sometimes you can have very disappointing results that are hard to explain. So we think that's been a really big issue that has caused a lot of problems in the field. And aside from the impact on clinical trial results, we also need to think about the future when these products are available and on the market, and how you can actually, in practical terms, produce enough of these products. So, in a nutshell, I think that is probably the major challenge that the field has faced."  #CynataTherapeutics #StemCellTherapy #RegenerativeMedicine #iPSCs #MSCs #MCAs Cynata.com Download the transcript here  

Shauna Sweeney, Founder of tendercare, aims to assist caregivers with digital tools and expert support to simplify the process of caring for an aging family member. Recognizing the essential role of caregivers in the quality of life of the patient, tendercare provides a user-friendly interface that incorporates data from wearables and remote sensors to identify early warning signs of risks, help coordinate care, and encourage proactive preparation. The Magic Magnet feature allows caregivers and emergency responders to quickly update and share critical health information.  Shauna explains, "This is not just a gendered issue. We have 54 million just Americans, if we keep it to the US, who are currently providing unpaid family care. This usually takes the form of anything from looking through bills, managing medications, renewing prescriptions, coordinating doctors' visits, and all other visits. Often, we find that those who are on our platform are the eldest child. So whether that's a daughter or a son, this is the type of person who is often leaning in to help. What is generally a parent or a grandparent who may or may not have the ability or the means to be able to get themselves to the doctor's appointments or pick up their prescriptions themselves, for instance." "Up until now, a lot of this has actually been human-powered. So, sitting down at the kitchen table with Mom and going through the mail to determine what needs to be paid by what time, but increasingly, because so many of us are living farther apart from one another, this is becoming more and more complicated. There is a level of coordination that we're all doing with one another, but we're often doing it over text. We're doing it over email, we're doing it over shared accounts and passwords. And so it's getting a lot more complicated, which is really where tendercare dropped in to try and help simplify a lot of this experience that so many of us are walking through right now." #Trytendercare #DigitalHealth #CareGiving #CareGivingTech #SmartCare #AginginPlace #HealthEquity trytendercare.com Listen to the podcast here

Shauna Sweeney, Founder of tendercare, aims to assist caregivers with digital tools and expert support to simplify the process of caring for an aging family member. Recognizing the essential role of caregivers in the quality of life of the patient, tendercare provides a user-friendly interface that incorporates data from wearables and remote sensors to identify early warning signs of risks, help coordinate care, and encourage proactive preparation. The Magic Magnet feature allows caregivers and emergency responders to quickly update and share critical health information.  Shauna explains, "This is not just a gendered issue. We have 54 million just Americans, if we keep it to the US, who are currently providing unpaid family care. This usually takes the form of anything from looking through bills, managing medications, renewing prescriptions, coordinating doctors' visits, and all other visits. Often, we find that those who are on our platform are the eldest child. So whether that's a daughter or a son, this is the type of person who is often leaning in to help. What is generally a parent or a grandparent who may or may not have the ability or the means to be able to get themselves to the doctor's appointments or pick up their prescriptions themselves, for instance." "Up until now, a lot of this has actually been human-powered. So, sitting down at the kitchen table with Mom and going through the mail to determine what needs to be paid by what time, but increasingly, because so many of us are living farther apart from one another, this is becoming more and more complicated. There is a level of coordination that we're all doing with one another, but we're often doing it over text. We're doing it over email, we're doing it over shared accounts and passwords. And so it's getting a lot more complicated, which is really where tendercare dropped in to try and help simplify a lot of this experience that so many of us are walking through right now."  #Trytendercare #DigitalHealth #CareGiving #CareGivingTech #SmartCare #AginginPlace #HealthEquity trytendercare.com Download the transcript here

Karen Sussman Horgan is the Co-Founder and CEO of VAL Health, a behavioral economics consulting firm that helps healthcare organizations drive engagement and nudge patients to improve their health and lifestyle choices. Behavioral economics is the science of understanding how patients make irrational choices based on biases, fear, and faulty analysis of outcomes and risk. Nudges can be carrots or sticks, but in healthcare, the focus is on making the right path easier to follow, reducing friction, and introducing positive reinforcements rather than penalties. Karen explains, "We work across the entire healthcare ecosystem. We think about digital health companies, how do you drive enrollment and engagement, and how do you optimize the journey? There are communications for that. We do a lot of work with payers, which is closing gaps in care, but also just improving the member experience in general with providers. It could be around provider adoption of new care pathways, but it's also about population health. We work with employers on wellness programs and pharma on that adherence. So think about where information alone isn't driving people to think about their health or take care of themselves. We create the nudges to help make that happen." "It's the science of understanding that we as humans are irrational. We have a bias toward the present. We have an aversion to loss and regret. We overweight probability. There are dozens of known biases, and what we do is harness them rather than asking people to change their biases. So let me give you a few examples to bring this to light because right now people are probably like, What is a bias? So think about Netflix when you watch an episode. First of all, you have choice overload when you get there. So it's giving you recommendations, but it also defaults you into the next episode because it plays on the fact that we have a status quo bias, and we're lazy, and we're just going to sit there and binge-watch. " #VALHealth  #BehavioralEconomics #BehavioralScience #BehaviorChange #DigitalHealth #Payers #HealthcareInnovation #HealthcareConsulting valhealth.com Listen to the podcast here    

Karen Sussman Horgan is the Co-Founder and CEO of VAL Health, a behavioral economics consulting firm that helps healthcare organizations drive engagement and nudge patients to improve their health and lifestyle choices. Behavioral economics is the science of understanding how patients make irrational choices based on biases, fear, and faulty analysis of outcomes and risk. Nudges can be carrots or sticks, but in healthcare, the focus is on making the right path easier to follow, reducing friction, and introducing positive reinforcements rather than penalties. Karen explains, "We work across the entire healthcare ecosystem. We think about digital health companies, how do you drive enrollment and engagement, and how do you optimize the journey? There are communications for that. We do a lot of work with payers, which is closing gaps in care, but also just improving the member experience in general with providers. It could be around provider adoption of new care pathways, but it's also about population health. We work with employers on wellness programs and pharma on that adherence. So think about where information alone isn't driving people to think about their health or take care of themselves. We create the nudges to help make that happen." "It's the science of understanding that we as humans are irrational. We have a bias toward the present. We have an aversion to loss and regret. We overweight probability. There are dozens of known biases, and what we do is harness them rather than asking people to change their biases. So let me give you a few examples to bring this to light because right now people are probably like, What is a bias? So think about Netflix when you watch an episode. First of all, you have choice overload when you get there. So it's giving you recommendations, but it also defaults you into the next episode because it plays on the fact that we have a status quo bias, and we're lazy, and we're just going to sit there and binge-watch. " #VALHealth  #BehavioralEconomics #BehavioralScience #BehaviorChange #DigitalHealth #Payers #HealthcareInnovation #HealthcareConsulting valhealth.com Download the transcript here  

Christine Lee, Head of Health Strategy and Partnerships at AnalyticsIQ, focuses on helping healthcare brands and pharmaceutical companies better understand and engage with healthcare providers by taking into account data beyond their professional lives. This data-driven Provider as a Person approach analyzes the healthcare professional's personal characteristics, outside interests, decision-making style, and preferred method of communication. The goal is to foster more meaningful relationships with providers, address provider burnout, and improve patient outcomes.   Christine explains, "We're coming into play here in supporting healthcare brands and better understanding the providers as people. As I mentioned, we're a people-based data company. I'd say that in an era where data is abundant and there is no shortage of health data being gathered and analyzed. So, you've got a lot of data assets out there that are coming from clinical trials, your real-world evidence, claims data, your electronic health records, all of which give insight into the aspects of a provider from a clinical setting. Traditionally, healthcare providers have been viewed primarily through the lens of their professional lives, their specialties, their role in patient care, prescription-writing behaviors, and even their affiliations. And these are super important factors. We do see those truly as table stakes, but they paint an incomplete picture."   "Providers, like patients, have unique lives, needs, and preferences, which really shape how they interact with the work they do and the brands they seek to engage with. The industry is really recognizing these nuances, which presents a unique opportunity for healthcare brands to acknowledge the complexity of the providers' lives beyond what you could say are their white coat moments, and differentiate their message. And so this can dig into driving more meaningful engagement. And for us here at AnalyticsIQ, we're focused on helping to understand healthcare providers, or HCPs, more broadly, and understanding some of their personal characteristics. So, the data we're bringing to the table to complement all the other data in the ecosystem will be things like considering their work-life balance." #AnalyticsIQ #HealthcareData #HealthcareAnalytics #HealthTech #HCPengagement #PatientExperience #ValueBasedCare #PersonalizedCare #HealthEquity #SDOH #HealthcarePrivacy #PatientData analytics-iq.com Listen to the podcast here

Christine Lee, Head of Health Strategy and Partnerships at AnalyticsIQ, focuses on helping healthcare brands and pharmaceutical companies better understand and engage with healthcare providers by taking into account data beyond their professional lives. This data-driven Provider as a Person approach analyzes the healthcare professional's personal characteristics, outside interests, decision-making style, and preferred method of communication. The goal is to foster more meaningful relationships with providers, address provider burnout, and improve patient outcomes.   Christine explains, "We're coming into play here in supporting healthcare brands and better understanding the providers as people. As I mentioned, we're a people-based data company. I'd say that in an era where data is abundant and there is no shortage of health data being gathered and analyzed. So, you've got a lot of data assets out there that are coming from clinical trials, your real-world evidence, claims data, your electronic health records, all of which give insight into the aspects of a provider from a clinical setting. Traditionally, healthcare providers have been viewed primarily through the lens of their professional lives, their specialties, their role in patient care, prescription-writing behaviors, and even their affiliations. And these are super important factors. We do see those truly as table stakes, but they paint an incomplete picture."   "Providers, like patients, have unique lives, needs, and preferences, which really shape how they interact with the work they do and the brands they seek to engage with. The industry is really recognizing these nuances, which presents a unique opportunity for healthcare brands to acknowledge the complexity of the providers' lives beyond what you could say are their white coat moments, and differentiate their message. And so this can dig into driving more meaningful engagement. And for us here at AnalyticsIQ, we're focused on helping to understand healthcare providers, or HCPs, more broadly, and understanding some of their personal characteristics. So, the data we're bringing to the table to complement all the other data in the ecosystem will be things like considering their work-life balance." #AnalyticsIQ #HealthcareData #HealthcareAnalytics #HealthTech #HCPengagement #PatientExperience #ValueBasedCare #PersonalizedCare #HealthEquity #SDOH #HealthcarePrivacy #PatientData analytics-iq.com Download the transcript here

Francisco Salva, President and CEO of Azitra, Inc., is leveraging the microbial bacteria that comprise the skin microbiome and exploring novel methods to deliver precision medicines to the skin. Azitra has genetically engineered specific strains of these microbes to produce proteins that are missing in patients with skin conditions like Netherton syndrome and cancer therapy-associated rashes. These bacterial strains have the ability to get beneath the stratum corneum and turn into miniature factories to make the therapeutic proteins and help the skin return to homeostasis. Francisco explains, "We're leveraging the billions of microbial bacteria that naturally live on us and are synergistic with our skin to help keep our skin in homeostasis or a regulated standard of existence. These bacteria makeup that are known as the skin microbiome, we have built up a library of these microbial bacteria strains commonly found on normal people and characterize them in a way that allows us to look for specific strains that may be able to deliver special proteins that may be missing or aberrantly made in the skin."   "What we're leveraging is that microbial strain's ability to get past the outer protective layer of the skin called the stratum corneum. And these microbial strains get through that outer layer through intermittent spaces between the hair and that outer skin layer, the stratum corneum, and are able to get underneath the stratum corneum, grow, multiply, and colonize. And so by genetically engineering specific strains of these microbes, we're able to synthetically, or also known as recombinantly, make proteins that are missing in the patient's skin." "It's a little bit newer than the gut microbiome, and the field of study is also a little bit newer. And so the development of the understanding of the microbiome, which is what they call the defined consortia of various strains that normally live on us, is not quite as well elucidated as it is in the gut microbiome. That said, our mission at Azitra isn't to try to reset the entire regulation of the entire skin microbiome, but really just leverage specific strains of these bacteria that have the ability to get underneath that external layer of the skin."   #RareDisease #OrphanDisease #Dermatology #SkinDisease #SkinDisorder #PrecisionsMedicine #PrecisionDermatology #PrecisionDerm #Netherton #NethertonSyndrome #Ichthyosis #CancerRash #EGFRiRash  #EGFRiTreament azitrainc.com Listen to the podcast here

Francisco Salva, President and CEO of Azitra, Inc., is leveraging the microbial bacteria that comprise the skin microbiome and exploring novel methods to deliver precision medicines to the skin. Azitra has genetically engineered specific strains of these microbes to produce proteins that are missing in patients with skin conditions like Netherton syndrome and cancer therapy-associated rashes. These bacterial strains have the ability to get beneath the stratum corneum and turn into miniature factories to make the therapeutic proteins and help the skin return to homeostasis. Francisco explains, "We're leveraging the billions of microbial bacteria that naturally live on us and are synergistic with our skin to help keep our skin in homeostasis or a regulated standard of existence. These bacteria makeup that are known as the skin microbiome, we have built up a library of these microbial bacteria strains commonly found on normal people and characterize them in a way that allows us to look for specific strains that may be able to deliver special proteins that may be missing or aberrantly made in the skin."   "What we're leveraging is that microbial strain's ability to get past the outer protective layer of the skin called the stratum corneum. And these microbial strains get through that outer layer through intermittent spaces between the hair and that outer skin layer, the stratum corneum, and are able to get underneath the stratum corneum, grow, multiply, and colonize. And so by genetically engineering specific strains of these microbes, we're able to synthetically, or also known as recombinantly, make proteins that are missing in the patient's skin." "It's a little bit newer than the gut microbiome, and the field of study is also a little bit newer. And so the development of the understanding of the microbiome, which is what they call the defined consortia of various strains that normally live on us, is not quite as well elucidated as it is in the gut microbiome. That said, our mission at Azitra isn't to try to reset the entire regulation of the entire skin microbiome, but really just leverage specific strains of these bacteria that have the ability to get underneath that external layer of the skin."   #RareDisease #OrphanDisease #Dermatology #SkinDisease #SkinDisorder #PrecisionsMedicine #PrecisionDermatology #PrecisionDerm #Netherton #NethertonSyndrome #Ichthyosis #CancerRash #EGFRiRash  #EGFRiTreament azitrainc.com Download the transcript here

Dr. Quyen Nguyen, CEO and Founder of Alume Biosciences, is developing fluorescent-guided precision surgery technologies that enable surgeons to visualize critical structures, such as nerves, blood vessels, and tumor margins, more clearly during procedures. Alume is developing fluorescent dyes and imaging systems to support this approach, building on work by Roger Tsien who won the Nobel Prize for fluorescence. This technology has the potential to enable more complex surgical procedures to be performed safely in brain, head, neck, and abdominal surgeries and has the promise to transform surgery. Quyen elaborates, "I first met Roger Tsien Nobel Laureate for his work in fluorescence, in 2001. I had worked with green fluorescent protein, one of the things that he was working on for fluorescence, and he ultimately was awarded the Nobel Prize for fluorescence. And I asked him, ‘Roger, is there a way we can make nerves fluorescent in patients? We certainly have that in research, but surgeons don't have this tool now.' And he said, ‘What, no one's done that yet?' And so that's the beginning of our story together. I see that the use of fluorescence is going to be transformative in the field of surgery. Who wants to turn off the light and see if surgeons can see and operate in the dark? So I feel like fluorescence is just another level of light that allows you to see structures more precisely." "Of course, you want to see structures more precisely so you can continue to carry on your work, tumor resection, reconstructive surgery, or any other procedures that patients are undergoing. Of course, you want to see tumor margins more clearly. Of course, you want to see arteries and veins and so forth. Of all the structures that we work on, I would say that nerves are considered the holy grail of surgery, partly because they're so delicate. One or two millimeters can take away somebody's ability to have urinary continence or erectile function or the ability to smile."   #AlumeBiosciences #FluorescentGuidedSurgery #PrecisionSurgery #HeadNeckSurgery AlumeBiosciences.com Listen to the podcast here

Dr. Quyen Nguyen, CEO and Founder of Alume Biosciences, is developing fluorescent-guided precision surgery technologies that enable surgeons to visualize critical structures, such as nerves, blood vessels, and tumor margins, more clearly during procedures. Alume is developing fluorescent dyes and imaging systems to support this approach, building on work by Roger Tsien who won the Nobel Prize for fluorescence. This technology has the potential to enable more complex surgical procedures to be performed safely in brain, head, neck, and abdominal surgeries and has the promise to transform surgery. Quyen elaborates, "I first met Roger Tsien Nobel Laureate for his work in fluorescence, in 2001. I had worked with green fluorescent protein, one of the things that he was working on for fluorescence, and he ultimately was awarded the Nobel Prize for fluorescence. And I asked him, ‘Roger, is there a way we can make nerves fluorescent in patients? We certainly have that in research, but surgeons don't have this tool now.' And he said, ‘What, no one's done that yet?' And so that's the beginning of our story together. I see that the use of fluorescence is going to be transformative in the field of surgery. Who wants to turn off the light and see if surgeons can see and operate in the dark? So I feel like fluorescence is just another level of light that allows you to see structures more precisely." "Of course, you want to see structures more precisely so you can continue to carry on your work, tumor resection, reconstructive surgery, or any other procedures that patients are undergoing. Of course, you want to see tumor margins more clearly. Of course, you want to see arteries and veins and so forth. Of all the structures that we work on, I would say that nerves are considered the holy grail of surgery, partly because they're so delicate. One or two millimeters can take away somebody's ability to have urinary continence or erectile function or the ability to smile."   #AlumeBiosciences #FluorescentGuidedSurgery #PrecisionSurgery #HeadNeckSurgery AlumeBiosciences.com Download the transcript here

Rob Armstrong, CEO of Artax Biopharma, highlights the basic mechanism of action of Nck modulators and how they differ from traditional immunosuppressant drugs to treat autoimmune diseases. Taking this adjustable thermostat approach aims to modulate the immune response rather than completely suppressing the response, potentially reducing side effects. The oral, small molecule drug is an advantage over injectable biologics currently dominating the automimmune disease treatment landscape. Rob explains, "Nck stands for non-catalytic kinase, and what Nck is is an adapter protein that interacts with the T cell receptor. Its role is basically to amplify any signals when an antigen is presented to the T cell receptor. It's really interesting because it's called signal one. In other words, it's the beginning of the immune cascade when an antigen is presented. And what's interesting is that it's upstream of what the target of most other drugs are, which are the cytokines that are the offending entities for many of the autoimmune diseases. So what Nck does basically is it amplifies different types of antigens that are bound to the T cell receptor." "So, T cell receptors are a fascinating construct of proteins because they need to address the binding of antigens that are across an incredibly different range of avidity. In other words, it has to be able to be activated by both very strong avidity antigens and weak antigens. So what Nck does is it amplifies the signal when the antigen is a weak antigen, but when it's a strong antigen, Nck is really not necessary at all. And that particular distinction is why we modulate the immune system instead of suppressing it."  #ArtaxPharma #AutoimmuneDiseases #AtopicDermatitis #immunomodulation #NckModulators #TCellActivation #psoriasis #Dermotology artaxbiopharma.com Listen to the podcast here

Rob Armstrong, CEO of Artax Biopharma, highlights the basic mechanism of action of Nck modulators and how they differ from traditional immunosuppressant drugs to treat autoimmune diseases. Taking this adjustable thermostat approach aims to modulate the immune response rather than completely suppressing the response, potentially reducing side effects. The oral, small molecule drug is an advantage over injectable biologics currently dominating the automimmune disease treatment landscape. Rob explains, "Nck stands for non-catalytic kinase, and what Nck is is an adapter protein that interacts with the T cell receptor. Its role is basically to amplify any signals when an antigen is presented to the T cell receptor. It's really interesting because it's called signal one. In other words, it's the beginning of the immune cascade when an antigen is presented. And what's interesting is that it's upstream of what the target of most other drugs are, which are the cytokines that are the offending entities for many of the autoimmune diseases. So what Nck does basically is it amplifies different types of antigens that are bound to the T cell receptor." "So, T cell receptors are a fascinating construct of proteins because they need to address the binding of antigens that are across an incredibly different range of avidity. In other words, it has to be able to be activated by both very strong avidity antigens and weak antigens. So what Nck does is it amplifies the signal when the antigen is a weak antigen, but when it's a strong antigen, Nck is really not necessary at all. And that particular distinction is why we modulate the immune system instead of suppressing it."  #ArtaxPharma #AutoimmuneDiseases #AtopicDermatitis #immunomodulation #NckModulators #TCellActivation #psoriasis #Dermotology artaxbiopharma.com Download the transcript here

Shyam Natarajan, Founder and CEO of Avenda Health, is utilizing the Unfold AI platform that combines imaging, pathology, and clinical data to provide a comprehensive 3D visualization of prostate cancer. This platform has demonstrated significantly higher accuracy than conventional imaging techniques, enabling physicians to make more informed diagnoses and treatment decisions. The technology has been integrated into the clinical workflow to provide real-time insights and precision-guided interventions, minimizing treatment-related side effects and preserving patient quality of life. Shyam explains, "Unfold AI is unique in that it's multimodal. We take in imaging biomarkers, pathology, and clinical information as input. And conventional imaging really doesn't show you exactly everywhere the cancer is. MRI today misses two-thirds of the disease by volume, and so imaging is really good at screening and that initial diagnosis. But when it comes time to decide how to treat patients, the standard of care is challenging today because, really, up to a third of patients end up having cancer left behind after treatment. So what we're trying to solve is this pain point where cancer is missed, and as a consequence, cancer is left behind." "This product is really for patients who have a diagnosis of what we call clinically significant or cancer that you have to do something about. So, it's not the very low-risk, where being on what's called surveillance, watch and wait, is probably more appropriate. But this product, you touched upon the value proposition where a lot of patients are coming to their doctor saying, Hey Doc, I don't want to get surgery because I'm scared of the quality of life outcomes or the side effect profile. They want to get a targeted therapy. Well, physicians really can't offer targeted therapy in a broad sense unless they know where the cancer is. And so, AI is empowering and enabling physicians to perform precision-guided therapy or focal therapy." #AvendaHealth #UnfoldAi #ProstateCancer #ProstateCancerTreatment #HealthcareAI #CancerAI #RadiologyAI #DiagnosticAI #MedicalAI #AIinHealthcare avendahealth.com Listen to the podcast here

Shyam Natarajan, Founder and CEO of Avenda Health, is utilizing the Unfold AI platform that combines imaging, pathology, and clinical data to provide a comprehensive 3D visualization of prostate cancer. This platform has demonstrated significantly higher accuracy than conventional imaging techniques, enabling physicians to make more informed diagnoses and treatment decisions. The technology has been integrated into the clinical workflow to provide real-time insights and precision-guided interventions, minimizing treatment-related side effects and preserving patient quality of life. Shyam explains, "Unfold AI is unique in that it's multimodal. We take in imaging biomarkers, pathology, and clinical information as input. And conventional imaging really doesn't show you exactly everywhere the cancer is. MRI today misses two-thirds of the disease by volume, and so imaging is really good at screening and that initial diagnosis. But when it comes time to decide how to treat patients, the standard of care is challenging today because, really, up to a third of patients end up having cancer left behind after treatment. So what we're trying to solve is this pain point where cancer is missed, and as a consequence, cancer is left behind."  "This product is really for patients who have a diagnosis of what we call clinically significant or cancer that you have to do something about. So, it's not the very low-risk, where being on what's called surveillance, watch and wait, is probably more appropriate. But this product, you touched upon the value proposition where a lot of patients are coming to their doctor saying, Hey Doc, I don't want to get surgery because I'm scared of the quality of life outcomes or the side effect profile. They want to get a targeted therapy. Well, physicians really can't offer targeted therapy in a broad sense unless they know where the cancer is. And so, AI is empowering and enabling physicians to perform precision-guided therapy or focal therapy." #AvendaHealth #UnfoldAi #ProstateCancer #ProstateCancerTreatment #HealthcareAI #CancerAI #RadiologyAI #DiagnosticAI #MedicalAI #AIinHealthcare avendahealth.com Download the transcript here

Richard Mackey, Chief Technology Officer at CCS, focuses on the challenges faced by patients with diabetes and multiple morbidities, as well as their healthcare providers, in managing their conditions.  CCS has developed the Living Connected approach to connect patients, providers, and payers, and promotes the role that durable medical equipment companies and pharmacists can play in supporting patients and doctors. Recognizing that patients are more than their disease, CCS addresses social determinants of health to provide education and care coordination. Richard explains, "CCS is a company that is in the business of chronic care management. We focus on delivering products and services to patients with a variety of chronic care conditions. But foremost among these for us is diabetes. We're very focused on being able to provide solutions and services for folks who are managing their diabetic condition."  "On the machine learning side, we have a tremendous amount of data and information about how our patients will understand the devices they might be using. For example, continuous glucose monitors or CGMs are an important standard of care that we work with a lot of patients across the US to equip them, find the right device, help them begin using that device, and best understand what it can do and how it can help them make better decisions to manage their conditions." "We might talk to the patient once or twice a month. We might be talking to them multiple times within a quarter. In some cases, we're interacting with a patient more often than others in the ecosystem, maybe more often than even their physician in terms of the number of interactions per month or period, even their health insurance provider. So all that interaction helps give us information and data to draw insights on what those patients might need, what's most important to them, and how they interact with us. We can also work with a variety of other sources to bring information together. And by using the machine learning tools that we've developed, we can understand things that are important to them. So, it might be around the product or specific information related to the plan or the payer they're working with." #CCSMed #Diabetes #ChronicCare #CGM #Healthcare #DigitalHealth #MedicalAI ccsmed.com Listen to the podcast here

Richard Mackey, Chief Technology Officer at CCS, focuses on the challenges faced by patients with diabetes and multiple morbidities, as well as their healthcare providers, in managing their conditions.  CCS has developed the Living Connected approach to connect patients, providers, and payers, and promotes the role that durable medical equipment companies and pharmacists can play in supporting patients and doctors. Recognizing that patients are more than their disease, CCS addresses social determinants of health to provide education and care coordination. Richard explains, "CCS is a company that is in the business of chronic care management. We focus on delivering products and services to patients with a variety of chronic care conditions. But foremost among these for us is diabetes. We're very focused on being able to provide solutions and services for folks who are managing their diabetic condition."  "On the machine learning side, we have a tremendous amount of data and information about how our patients will understand the devices they might be using. For example, continuous glucose monitors or CGMs are an important standard of care that we work with a lot of patients across the US to equip them, find the right device, help them begin using that device, and best understand what it can do and how it can help them make better decisions to manage their conditions." "We might talk to the patient once or twice a month. We might be talking to them multiple times within a quarter. In some cases, we're interacting with a patient more often than others in the ecosystem, maybe more often than even their physician in terms of the number of interactions per month or period, even their health insurance provider. So all that interaction helps give us information and data to draw insights on what those patients might need, what's most important to them, and how they interact with us. We can also work with a variety of other sources to bring information together. And by using the machine learning tools that we've developed, we can understand things that are important to them. So, it might be around the product or specific information related to the plan or the payer they're working with." #CCSMed #Diabetes #ChronicCare #CGM #Healthcare #DigitalHealth #MedicalAI ccsmed.com Download the transcript here

Catherine Richards Golini, Patient Resource Manager at Karger Publishers, is providing high-quality, accurate healthcare information to patients, addressing the need for trusted health information. Karger has a rigorous process in place to ensure the relevance of its patient resources, involving patients, clinical reviewers, and obtaining a quality mark. With the increasing use of AI and healthcare influencers, healthcare providers need these resources to have more productive conversations with patients and encourage health literacy. Catherine explains, "I will refer to the patient resources we publish. We also produce resources for healthcare professionals, as you know. But my job is patient resources, and I think we're quite proud of our patient resources in the sense that we have a very watertight production process that involves patients from the very beginning. So we're confident that we're producing relevant information that's very important, relevant to the patient community, and what they want. Accuracy. We always involve clinical reviewers, usually two for each patient resource actually, to make sure that the content is accurate." "We've also got something called the PIF TICK, which is a British thing, but I believe it's now spreading across Europe. It may even be known of in the States. And the PIF TICK is like a quality mark, a certification mark for patient healthcare information. We have to have our resources, our production processes, and our resources evaluated. When we pass the evaluation, and there are about 10 criteria with multiple sub-criteria, we get the right to use this PIF TICK on the back of our resources. So those are three ways to guarantee that we produce trusted, accurate healthcare information for patients."  #KargerPublishers #Publishing #Science #Research #HealthInformation #MedicalAI #AI  karger.com   Listen to the podcast here

Catherine Richards Golini, Patient Resource Manager at Karger Publishers, is providing high-quality, accurate healthcare information to patients, addressing the need for trusted health information. Karger has a rigorous process in place to ensure the relevance of its patient resources, involving patients, clinical reviewers, and obtaining a quality mark. With the increasing use of AI and healthcare influencers, healthcare providers need these resources to have more productive conversations with patients and encourage health literacy. Catherine explains, "I will refer to the patient resources we publish. We also produce resources for healthcare professionals, as you know. But my job is patient resources, and I think we're quite proud of our patient resources in the sense that we have a very watertight production process that involves patients from the very beginning. So we're confident that we're producing relevant information that's very important, relevant to the patient community, and what they want. Accuracy. We always involve clinical reviewers, usually two for each patient resource actually, to make sure that the content is accurate." "We've also got something called the PIF TICK, which is a British thing, but I believe it's now spreading across Europe. It may even be known of in the States. And the PIF TICK is like a quality mark, a certification mark for patient healthcare information. We have to have our resources, our production processes, and our resources evaluated. When we pass the evaluation, and there are about 10 criteria with multiple sub-criteria, we get the right to use this PIF TICK on the back of our resources. So those are three ways to guarantee that we produce trusted, accurate healthcare information for patients."  #KargerPublishers #Publishing #Science #Research #HealthInformation #MedicalAI #AI  karger.com  Download the transcript here

Dr. Orit Wimpfheimer, Chief Medical Officer at Nanox, a medical imaging AI company using technology to detect early signs of diseases through opportunistic screening of CT scans. The AI platform identifies signs of diseases such as osteoporosis and cardiovascular disease that may have been overlooked by the radiologist. The tools are designed to be integrated into the radiologist's workflow to provide quantified measurements to guide clinical care decisions leading to improved patient outcomes.   Orit explains, "The number of CT scans over the last 20 years has risen astronomically. People are getting CT scans for many reasons, and there's a lot of data on the images that doesn't get translated into patient care. And what our AI tools do is to scan all those CT scans in the background unobtrusively, so they look for signs of chronic conditions and highlight those to the radiologists while they're reading the scans. This ensures that chronic diseases are commented on in the reports, initiating a clinical pathway to help treat those diseases at the early stages of their disease processes. Ultimately, we're trying to find diseases much earlier to treat them much better and therefore increase the quality of life and the length of life by treating these diseases before they become very symptomatic." "So our tools are actually measurement tools. When the radiologist looks at the images, they have their checklist in their mind, myself included. I'm a radiologist. Things we're always looking for on the scan, and then we pay attention based on the patient's clinical history or rule out pneumonia, rule out cancer, whatever it is. Sometimes these chronic diseases might be lurking in the background, but they don't get attention from the radiologist. And even if the radiologist is super careful and tries to find everything on the exam, we don't have time to start measuring things. And when you comment on something without giving a quantified measurement, it's very hard for the clinician down the line to know what to do with this patient. It's too vague. When we give quantified information, the doctor, after the radiologist, can take that quantified information and then know where to send the patient next and what to do next with the patient. And that's critical because we don't want to drop patients along the way, the clinical care pathway, because then it's ineffective." #NanoxVision #AIinHealthcare #HealthcareAI #MedAI #RadiologyAI #HealthcareInnovation #Medical Imaging #Radiology #EarlyDetection #PreventiveCare #PatientCare  nanox.vision Download the transcript here

Chelsey Lindner, a pharmacist and Manager of Clinical Services at Shields Health Solutions, provides insights about the growing prevalence of oral and subcutaneous injection oncology medications, which is shifting the delivery of care from the clinic to at-home. This innovation in cancer care introduces complexities around accessing and affording these specialty drugs and requires the skills of a specialty pharmacy to support the patients and providers. In an integrated care model, there is also a growing need for attention to medication adherence and monitoring for side effects by these pharmacists.   Chelsey explains, "Shields is considered a specialty pharmacy integrator. We partner with health systems across the country to help them operate best-in-class specialty pharmacy programs. We are focused on improving patient outcomes through specialized pharmacy services and supporting the optimized use of specialty medications through navigation of access, care coordination, and comprehensive medication management. So those are three of the big services Shields offers as a company." "I would say that the number one component that these oral oncology medications offer is a level of patient convenience and maintenance of their quality of life. Because what was a cancer diagnosis 20 years ago meant they were going to have to come to the health center or be admitted to the hospital to receive their treatment. Whereas now, when a patient might be faced with a certain cancer diagnosis, they will be managing it like a chronic condition. They can stay at home, they can stay with their families. They can do all of those things that they want to do that help support that quality of life as they're going through active cancer treatment. And so with that certainly comes, I think, a level of popularity. And I think the pharmaceutical companies certainly would be incentivized to continue the research in this area and the development of these agents." #ShieldsHealthSolutions #IntegratedCareModel #SpecialtyPharmacy #CancerTreatment #MedicationAdherence shieldshealthsolutions.com Listen to the podcast here

Chelsey Lindner, a pharmacist and Manager of Clinical Services at Shields Health Solutions, provides insights about the growing prevalence of oral and subcutaneous injection oncology medications, which is shifting the delivery of care from the clinic to at-home. This innovation in cancer care introduces complexities around accessing and affording these specialty drugs and requires the skills of a specialty pharmacy to support the patients and providers. In an integrated care model, there is also a growing need for attention to medication adherence and monitoring for side effects by these pharmacists.   Chelsey explains, "Shields is considered a specialty pharmacy integrator. We partner with health systems across the country to help them operate best-in-class specialty pharmacy programs. We are focused on improving patient outcomes through specialized pharmacy services and supporting the optimized use of specialty medications through navigation of access, care coordination, and comprehensive medication management. So those are three of the big services Shields offers as a company." "I would say that the number one component that these oral oncology medications offer is a level of patient convenience and maintenance of their quality of life. Because what was a cancer diagnosis 20 years ago meant they were going to have to come to the health center or be admitted to the hospital to receive their treatment. Whereas now, when a patient might be faced with a certain cancer diagnosis, they will be managing it like a chronic condition. They can stay at home, they can stay with their families. They can do all of those things that they want to do that help support that quality of life as they're going through active cancer treatment. And so with that certainly comes, I think, a level of popularity. And I think the pharmaceutical companies certainly would be incentivized to continue the research in this area and the development of these agents." #ShieldsHealthSolutions #IntegratedCareModel #SpecialtyPharmacy #CancerTreatment #MedicationAdherence shieldshealthsolutions.com Listen to the podcast here

Chelsey Lindner, a pharmacist and Manager of Clinical Services at Shields Health Solutions, provides insights about the growing prevalence of oral and subcutaneous injection oncology medications, which is shifting the delivery of care from the clinic to at-home. This innovation in cancer care introduces complexities around accessing and affording these specialty drugs and requires the skills of a specialty pharmacy to support the patients and providers. In an integrated care model, there is also a growing need for attention to medication adherence and monitoring for side effects by these pharmacists.   Chelsey explains, "Shields is considered a specialty pharmacy integrator. We partner with health systems across the country to help them operate best-in-class specialty pharmacy programs. We are focused on improving patient outcomes through specialized pharmacy services and supporting the optimized use of specialty medications through navigation of access, care coordination, and comprehensive medication management. So those are three of the big services Shields offers as a company." "I would say that the number one component that these oral oncology medications offer is a level of patient convenience and maintenance of their quality of life. Because what was a cancer diagnosis 20 years ago meant they were going to have to come to the health center or be admitted to the hospital to receive their treatment. Whereas now, when a patient might be faced with a certain cancer diagnosis, they will be managing it like a chronic condition. They can stay at home, they can stay with their families. They can do all of those things that they want to do that help support that quality of life as they're going through active cancer treatment. And so with that certainly comes, I think, a level of popularity. And I think the pharmaceutical companies certainly would be incentivized to continue the research in this area and the development of these agents." #ShieldsHealthSolutions #IntegratedCareModel #SpecialtyPharmacy #CancerTreatment #MedicationAdherence shieldshealthsolutions.com Download the transcript here

Tamsin Chislett, CEO of Hyfe, highlights the importance of understanding coughs for healthcare providers, the lack of information about coughs, and Hyfe's advancements in building a database and developing biomarkers based on different kinds of coughs. Hyfe's AI technology, which can integrate with other devices and platforms for remote patient monitoring, enables passive, continuous tracking of cough patterns that can be used in research and clinical trials. Opportunities for digital therapeutics include chronic cough, COPD, lung cancer, respiratory infections, and cardiovascular diseases.  Tamsin elaborates, "Hyfe is the global leader in AI power. The problem we're trying to solve is that you have this really common symptom cough, which has been experienced by every human alive and is experienced daily by many people, yet to discuss it, measure it, monitor it, or even manage it, we're entirely reliant on subjective data. Everyone's had the experience of going into a primary care doctor, and saying I've got a really bad cough. The doctor says How bad is it, and is it getting worse?  We don't even have the proper language to describe it." "We want to get to the point where, in those situations, the doctor can start to get objective data about the patient's cough patterns and use that instead. The way we see it is that there was a time when to measure fever, we put a hand on a patient's forehead. We hope that within a few years, thanks to Hyfe's technology, we should not be in the same position with cough. So we're always looking to have objective data." "I think the interesting thing about cough is that because it's never been measurable, it hasn't been studied anywhere near as much as it probably should have. And even in the first five years of Hyfe's life, we've seen an explosion in cough-related science now that it's possible to monitor coughs with a smartphone, a smart watch, or anything with a microphone running Hyfe's technology. We've seen exciting science across a whole range, many of which are intuitive when you start thinking about cough, acute cough is a big one and respiratory infections, but there's also chronic cough."  "There's also COPD, there's IPF, there's lung cancer, there are so many respiratory and even cardiology diseases where cough is a cardinal symptom, a really clear sign of exacerbation of disease or worsening. However, to date, it has not been able to be measured, and cough monitoring with Hyfe allows you to monitor cough over time, see patterns, and use those patterns to optimize patient care in the future." #HyfeAI #ChronicCough #HyfeDTx #DigitalHealth #AIinHealthcare #DigitalTherapeutics #MedAI #CoughMonitoring #RemotePatientMonitoring #HealthInnovation #RespiratoryAwareness #CoughAwareness #CoughScience #PatientCentricCare hyfe.com Listen to the podcast here

Tamsin Chislett, CEO of Hyfe, highlights the importance of understanding coughs for healthcare providers, the lack of information about coughs, and Hyfe's advancements in building a database and developing biomarkers based on different kinds of coughs. Hyfe's AI technology, which can integrate with other devices and platforms for remote patient monitoring, enables passive, continuous tracking of cough patterns that can be used in research and clinical trials. Opportunities for digital therapeutics include chronic cough, COPD, lung cancer, respiratory infections, and cardiovascular diseases.  Tamsin elaborates, "Hyfe is the global leader in AI power. The problem we're trying to solve is that you have this really common symptom cough, which has been experienced by every human alive and is experienced daily by many people, yet to discuss it, measure it, monitor it, or even manage it, we're entirely reliant on subjective data. Everyone's had the experience of going into a primary care doctor, and saying I've got a really bad cough. The doctor says How bad is it, and is it getting worse?  We don't even have the proper language to describe it." "We want to get to the point where, in those situations, the doctor can start to get objective data about the patient's cough patterns and use that instead. The way we see it is that there was a time when to measure fever, we put a hand on a patient's forehead. We hope that within a few years, thanks to Hyfe's technology, we should not be in the same position with cough. So we're always looking to have objective data." "I think the interesting thing about cough is that because it's never been measurable, it hasn't been studied anywhere near as much as it probably should have. And even in the first five years of Hyfe's life, we've seen an explosion in cough-related science now that it's possible to monitor coughs with a smartphone, a smart watch, or anything with a microphone running Hyfe's technology. We've seen exciting science across a whole range, many of which are intuitive when you start thinking about cough, acute cough is a big one and respiratory infections, but there's also chronic cough."  "There's also COPD, there's IPF, there's lung cancer, there are so many respiratory and even cardiology diseases where cough is a cardinal symptom, a really clear sign of exacerbation of disease or worsening. However, to date, it has not been able to be measured, and cough monitoring with Hyfe allows you to monitor cough over time, see patterns, and use those patterns to optimize patient care in the future." #HyfeAI #ChronicCough #HyfeDTx #DigitalHealth #AIinHealthcare #DigitalTherapeutics #MedAI #CoughMonitoring #RemotePatientMonitoring #HealthInnovation #RespiratoryAwareness #CoughAwareness #CoughScience #PatientCentricCare hyfe.com Download the transcript here

Dr. Orit Wimpfheimer, Chief Medical Officer at Nanox, a medical imaging AI company using technology to detect early signs of diseases through opportunistic screening of CT scans. The AI platform identifies signs of diseases such as osteoporosis and cardiovascular disease that may have been overlooked by the radiologist. The tools are designed to be integrated into the radiologist's workflow to provide quantified measurements to guide clinical care decisions leading to improved patient outcomes.   Orit explains, "The number of CT scans over the last 20 years has risen astronomically. People are getting CT scans for many reasons, and there's a lot of data on the images that doesn't get translated into patient care. And what our AI tools do is to scan all those CT scans in the background unobtrusively, so they look for signs of chronic conditions and highlight those to the radiologists while they're reading the scans. This ensures that chronic diseases are commented on in the reports, initiating a clinical pathway to help treat those diseases at the early stages of their disease processes. Ultimately, we're trying to find diseases much earlier to treat them much better and therefore increase the quality of life and the length of life by treating these diseases before they become very symptomatic." "So our tools are actually measurement tools. When the radiologist looks at the images, they have their checklist in their mind, myself included. I'm a radiologist. Things we're always looking for on the scan, and then we pay attention based on the patient's clinical history or rule out pneumonia, rule out cancer, whatever it is. Sometimes these chronic diseases might be lurking in the background, but they don't get attention from the radiologist. And even if the radiologist is super careful and tries to find everything on the exam, we don't have time to start measuring things. And when you comment on something without giving a quantified measurement, it's very hard for the clinician down the line to know what to do with this patient. It's too vague. When we give quantified information, the doctor, after the radiologist, can take that quantified information and then know where to send the patient next and what to do next with the patient. And that's critical because we don't want to drop patients along the way, the clinical care pathway, because then it's ineffective." #NanoxVision #AIinHealthcare #HealthcareAI #MedAI #RadiologyAI #HealthcareInnovation #Medical Imaging #Radiology #EarlyDetection #PreventiveCare #PatientCare  nanox.vision Listen to the podcast here

Geoff Nau, Senior Manager of Product Management for Paragon at Altera Digital Health, highlights how digital health solutions can address the challenges of nurse burnout and retention. AI and machine learning can help automate documentation tasks and streamline workflows to allow nurses better access to patient information. Improving nurse retention requires attention to factors like time-off policies and leveraging technology to give nurses more time to focus on patient care. Geoff elaborates, "I have been a nurse since 2004. I practiced at the bedside for approximately 15 years. I did pediatric and adult ER as well as NICU. So I started my nursing career on paper and transitioned to electronic. And so in that time, a couple of factors, in the beginning, there was not enough information, and click-intensive. And looking at my travels and going to hospitals and sites today, that challenge is still there as far as access to data relevant to that patient visit, whether it's trending labs, care plans, etc. My experience with most EHRs out there, most of all, is that it's just click-intensive. A one-size-fits-all is tough to do nowadays." "There is still a considerable amount of paper out there. When you start getting into these specialized areas like behavioral health, IOP or intensive outpatient, a lot of that, especially if there's anything like a treatment plan, things that may have multiple people needing to touch it, I still see a lot of that on paper. My goal from a solutions perspective is to get as much of that electronic as possible, especially given where we're at with challenges with nursing and staffing. Today, your patient loads go from four to five to one nurse." "I'm a nurse. I also have a doctorate in organizational psychology. And this was a big study of my focus during my dissertation, where I looked at why people stay on the job as opposed to why they leave. When I first got into nursing, nurses would leave for a dollar. They would go up the street to another facility. But now, having support systems in place allows nurses to take time off, as you said. I know that here, where I live in North Carolina, a couple of institutions are taking a look at their PTO policies. They're looking at their holiday policies and trying to be more flexible. They're working with PRN staffing. In my research, I also found a community component to job embeddedness, if you will, in nursing." #AlteraDigitalHealth #DigitalHealth #Nurses #Nursing #NurseBurnout #NurseRetention #MedAI alterahealth.com Listen to the podcast here

Geoff Nau, Senior Manager of Product Management for Paragon at Altera Digital Health, highlights how digital health solutions can address the challenges of nurse burnout and retention. AI and machine learning can help automate documentation tasks and streamline workflows to allow nurses better access to patient information. Improving nurse retention requires attention to factors like time-off policies and leveraging technology to give nurses more time to focus on patient care. Geoff elaborates, "I have been a nurse since 2004. I practiced at the bedside for approximately 15 years. I did pediatric and adult ER as well as NICU. So I started my nursing career on paper and transitioned to electronic. And so in that time, a couple of factors, in the beginning, there was not enough information, and click-intensive. And looking at my travels and going to hospitals and sites today, that challenge is still there as far as access to data relevant to that patient visit, whether it's trending labs, care plans, etc. My experience with most EHRs out there, most of all, is that it's just click-intensive. A one-size-fits-all is tough to do nowadays." "There is still a considerable amount of paper out there. When you start getting into these specialized areas like behavioral health, IOP or intensive outpatient, a lot of that, especially if there's anything like a treatment plan, things that may have multiple people needing to touch it, I still see a lot of that on paper. My goal from a solutions perspective is to get as much of that electronic as possible, especially given where we're at with challenges with nursing and staffing. Today, your patient loads go from four to five to one nurse." "I'm a nurse. I also have a doctorate in organizational psychology. And this was a big study of my focus during my dissertation, where I looked at why people stay on the job as opposed to why they leave. When I first got into nursing, nurses would leave for a dollar. They would go up the street to another facility. But now, having support systems in place allows nurses to take time off, as you said. I know that here, where I live in North Carolina, a couple of institutions are taking a look at their PTO policies. They're looking at their holiday policies and trying to be more flexible. They're working with PRN staffing. In my research, I also found a community component to job embeddedness, if you will, in nursing." #AlteraDigitalHealth #DigitalHealth #Nurses #Nursing #NurseBurnout #NurseRetention #MedAI alterahealth.com Download the transcript here

Dr. Paul Moore, Chief Scientific Officer at Zymeworks, focuses on developing targeted therapies, particularly multispecific antibodies and antibody-drug conjugates for hard-to-treat cancers such as gynecological, thoracic, and digestive tract cancers. This approach can target multiple areas on tumor cells and immune cells, potentially overcoming tumor heterogeneity and allowing for immune system modulation. The platform allows for a plug-and-play approach, enabling the development of therapies for oncology and autoimmune diseases.  Paul explains, "So, multispecific antibodies are antibodies. Antibodies traditionally have a single target that they bind, so they're monoclonal and hit a specific target. A lot of excitement is generated for bispecific antibodies, which are engineered to bind two targets. Then with multispecifics, you are trying to broaden even further the number of targets or binding sites you've incorporated into your drug so that you can simultaneously interact with more than one target. The reason that can be important is that allows and facilitates new biology that is not possible for just a monoclonal antibody or a single antibody-targeting drug conjugate."   "Multispecifics open up the opportunity to take two targets that are on different cells, different cell populations. So, you can have a target on a tumor cell you're trying to target. Then you can have a target on an immune cell like a T cell, which you can co-engage. You can bridge a T cell to a binding domain that's on a multispecific with your second specificity, which can bind to the cell.  And what that allows you to do is bring the T cell into the environment of the tumor cell, and through that engagement, the T cell can kill the tumor cell.  So that is the foundation of a lot of excitement in bispecifics." #Zymeworks #Antibodies #MultispecificAntibodies #ADC #AntibodyDrugConjugate #Tumors #Cancer #ImmuneSystem zymeworks.com Listen to the podcast here

Dr. Paul Moore, Chief Scientific Officer at Zymeworks, focuses on developing targeted therapies, particularly multispecific antibodies and antibody-drug conjugates for hard-to-treat cancers such as gynecological, thoracic, and digestive tract cancers. This approach can target multiple areas on tumor cells and immune cells, potentially overcoming tumor heterogeneity and allowing for immune system modulation. The platform allows for a plug-and-play approach, enabling the development of therapies for oncology and autoimmune diseases.  Paul explains, "So, multispecific antibodies are antibodies. Antibodies traditionally have a single target that they bind, so they're monoclonal and hit a specific target. A lot of excitement is generated for bispecific antibodies, which are engineered to bind two targets. Then with multispecifics, you are trying to broaden even further the number of targets or binding sites you've incorporated into your drug so that you can simultaneously interact with more than one target. The reason that can be important is that allows and facilitates new biology that is not possible for just a monoclonal antibody or a single antibody-targeting drug conjugate."   "Multispecifics open up the opportunity to take two targets that are on different cells, different cell populations. So, you can have a target on a tumor cell you're trying to target. Then you can have a target on an immune cell like a T cell, which you can co-engage. You can bridge a T cell to a binding domain that's on a multispecific with your second specificity, which can bind to the cell.  And what that allows you to do is bring the T cell into the environment of the tumor cell, and through that engagement, the T cell can kill the tumor cell.  So that is the foundation of a lot of excitement in bispecifics." #Zymeworks #Antibodies #MultispecificAntibodies #ADC #AntibodyDrugConjugate #Tumors #Cancer #ImmuneSystem zymeworks.com Download the transcript here

Dr. Sonja Tarrago, head of Physician Strategy and Engagement at DexCare, has created a care orchestration platform to help health systems improve patient access to care, direct patients to the proper care, and optimize provider capacity. DexCare solutions have enabled health systems to treat more patients with existing resources, increase new patient acquisition, and reduce time to care. This platform reduces long wait times, provides real-time online scheduling, and matches patient demand with provider availability.   Sonja explains, "DexCare is a care orchestration platform used by leading health systems to help manage the supply and demand of healthcare. That means that our platform helps health systems get discovered at the point of search. So, where patients are searching for care, we know that's typically Google, and then we navigate patients to the best fit care. So we do that while optimizing provider capacity and resources in real time. So, as we talk about our customers, we think that first of all, we need to acknowledge that healthcare is in crisis right now." "In addition to making care more discoverable, we're using data to help direct our patients to the right care based on what they're looking for. This makes sure that the patients are getting connected to the right resources within the health systems that we work with, and we're helping to reduce bottlenecks and improve efficiencies within the health system."   "So we need to help patients find care, not find a doctor. In addition to that, I think another gap is that patients have limited access to real-time online scheduling. And by that, I don't mean a form that a patient fills out and waits for someone to get back to them. I mean a real-time slot that patients can book into."  #DexCare #CareOrchestration #DigitalHealth #CareOptimization dexcare.com Listen to the podcast here

Dr. Sonja Tarrago, head of Physician Strategy and Engagement at DexCare, has created a care orchestration platform to help health systems improve patient access to care, direct patients to the proper care, and optimize provider capacity. DexCare solutions have enabled health systems to treat more patients with existing resources, increase new patient acquisition, and reduce time to care. This platform reduces long wait times, provides real-time online scheduling, and matches patient demand with provider availability.   Sonja explains, "DexCare is a care orchestration platform used by leading health systems to help manage the supply and demand of healthcare. That means that our platform helps health systems get discovered at the point of search. So, where patients are searching for care, we know that's typically Google, and then we navigate patients to the best fit care. So we do that while optimizing provider capacity and resources in real time. So, as we talk about our customers, we think that first of all, we need to acknowledge that healthcare is in crisis right now." "In addition to making care more discoverable, we're using data to help direct our patients to the right care based on what they're looking for. This makes sure that the patients are getting connected to the right resources within the health systems that we work with, and we're helping to reduce bottlenecks and improve efficiencies within the health system."   "So we need to help patients find care, not find a doctor. In addition to that, I think another gap is that patients have limited access to real-time online scheduling. And by that, I don't mean a form that a patient fills out and waits for someone to get back to them. I mean a real-time slot that patients can book into."  #DexCare #CareOrchestration #DigitalHealth #CareOptimization dexcare.com Download the transcript here

David Norris, Founder and CEO of Affineon Health Inc., recognizes the significant problem of provider burnout, which is primarily caused by the time doctors spend on administrative tasks rather than with the patient. Affineon's AI-powered solution aims to address this by automating the review of the provider's inbox and reducing their cognitive load. The inboxes are filled with lab results, pharmacy messages, and other tasks that need review. This approach enables doctors to focus on the required actions quickly. David explains, "We're attacking one of the biggest problems providers often complain about: the inbox. And this is their clinical inbox, not their email inbox like you and I have. The clinical inbox is typically filled with hundreds of things that come in daily. For a PCP, this can often include things like lab results. So you go to your doctor for your annual wellness visit, and they order five to 10 different labs, which come into their inbox the next day. If you're seeing 20 patients a day, that's hundreds of results, plus you're getting prescription renewal requests from the pharmacies, you're getting patient messages. The provider, while trying to stay focused on seeing 20 patients a day and keeping their focus on those patients, they're now literally trying to squeeze a little inbox time in before and after patients."   "Affineon has introduced an AI inbox that integrates directly into the electronic health record system. We do exactly what you would do if you hired an assistant in the medical terminology, triage your inbox, which is to handle everything they can handle. The provider focuses on the most critical things. So we're using an AI agent to do that, and unlike a human, which would be very costly to do this, our solution costs $2.50 a day. So about half a cup of coffee. So, for a provider to now have the ability to have an assistant triage their inbox every day and to help them by reducing their daily inbox volume by up to 50%-60%, that's pretty incredible. And before AI, that wasn't possible."  #Affineon #MedAI #ProviderBurnout #AIInbox affineon.com Listen to the podcast here  

David Norris, Founder and CEO of Affineon Health Inc., recognizes the significant problem of provider burnout, which is primarily caused by the time doctors spend on administrative tasks rather than with the patient. Affineon's AI-powered solution aims to address this by automating the review of the provider's inbox and reducing their cognitive load. The inboxes are filled with lab results, pharmacy messages, and other tasks that need review. This approach enables doctors to focus on the required actions quickly. David explains, "We're attacking one of the biggest problems providers often complain about: the inbox. And this is their clinical inbox, not their email inbox like you and I have. The clinical inbox is typically filled with hundreds of things that come in daily. For a PCP, this can often include things like lab results. So you go to your doctor for your annual wellness visit, and they order five to 10 different labs, which come into their inbox the next day. If you're seeing 20 patients a day, that's hundreds of results, plus you're getting prescription renewal requests from the pharmacies, you're getting patient messages. The provider, while trying to stay focused on seeing 20 patients a day and keeping their focus on those patients, they're now literally trying to squeeze a little inbox time in before and after patients."   "Affineon has introduced an AI inbox that integrates directly into the electronic health record system. We do exactly what you would do if you hired an assistant in the medical terminology, triage your inbox, which is to handle everything they can handle. The provider focuses on the most critical things. So we're using an AI agent to do that, and unlike a human, which would be very costly to do this, our solution costs $2.50 a day. So about half a cup of coffee. So, for a provider to now have the ability to have an assistant triage their inbox every day and to help them by reducing their daily inbox volume by up to 50%-60%, that's pretty incredible. And before AI, that wasn't possible."  #Affineon #MedAI #ProviderBurnout #AIInbox affineon.com Download the transcript here  

Dr. Jason Williams, President and Director of Interventional Oncology and Immunotherapy at the Williams Cancer Institute, uses a combination of Pulse Electric Field technology to ablate tumors and direct injection of immunotherapy drugs into the tumor to stimulate the immune system. This approach can be used in conjunction with traditional cancer treatments and has fewer side effects than standard immunotherapy. This method is part of the broader trend in cancer research to provide a more targeted approach to treating tumors. Jason explains, "Our big focus is going to the tumor itself, so we do treatments directly at the tumor, and we do a combination of things. We do things that will be considered ablation where we're using different technologies or energies — I'll explain — particularly, we use one called Pulse Electric Field (PEF), which kills the tumor by essentially shocking it, and that kills it in a way that actually makes the immune system see it better. You're not trying to kill all of the tumor, you're trying to kill pieces for the immune system. Then we inject drugs into that area of the tumor, particularly immunotherapy drugs, but it can be other drugs as well, and just really taking the fight to the cancer right in the tumor." "I think that our mistake in cancer treatments is that we're not addressing the tumors directly. I mean, it's one thing to expect that you're going to take a drug orally or intravenously and that it's going to arrive and make it to the cancer cells. Still, the other way is to go right into it, putting the drugs there, and particularly with immunotherapies, where you want to attract the immune system to it. You want those drugs in the cancer, you don't want them just everywhere in the body." #WilliamsCancer #Cancer #Oncology #Tumors #Immunotherapy #PulseElectricField #ImmuneSystem #TargetingTumors WilliamsCancerInstitute.com Listen to the podcast here

Dr. Jason Williams, President and Director of Interventional Oncology and Immunotherapy at the Williams Cancer Institute, uses a combination of Pulse Electric Field technology to ablate tumors and direct injection of immunotherapy drugs into the tumor to stimulate the immune system. This approach can be used in conjunction with traditional cancer treatments and has fewer side effects than standard immunotherapy. This method is part of the broader trend in cancer research to provide a more targeted approach to treating tumors. Jason explains, "Our big focus is going to the tumor itself, so we do treatments directly at the tumor, and we do a combination of things. We do things that will be considered ablation where we're using different technologies or energies — I'll explain — particularly, we use one called Pulse Electric Field (PEF), which kills the tumor by essentially shocking it, and that kills it in a way that actually makes the immune system see it better. You're not trying to kill all of the tumor, you're trying to kill pieces for the immune system. Then we inject drugs into that area of the tumor, particularly immunotherapy drugs, but it can be other drugs as well, and just really taking the fight to the cancer right in the tumor." "I think that our mistake in cancer treatments is that we're not addressing the tumors directly. I mean, it's one thing to expect that you're going to take a drug orally or intravenously and that it's going to arrive and make it to the cancer cells. Still, the other way is to go right into it, putting the drugs there, and particularly with immunotherapies, where you want to attract the immune system to it. You want those drugs in the cancer, you don't want them just everywhere in the body." #WilliamsCancer #Cancer #Oncology #Tumors #Immunotherapy #PulseElectricField #ImmuneSystem #TargetingTumors WilliamsCancerInstitute.com Download the transcript here

Joel Stanley is the CEO of Ajna Biosciences, a company developing the next generation of botanical medicines. These full-spectrum drugs, derived from plants and fungi, are regulated and approved through the FDA, unlike dietary supplements. Lead drug candidates are targeting autism, generalized anxiety disorder, and PTSD. With expertise in cultivating and scaling the production of botanical raw materials, Ajna is creating a sustainable model compared to wild-harvested botanicals. Joel explains, "It's no secret that before about a hundred years ago, all of our medicines were botanical medicines, or mostly coming from plants, or maybe mushrooms. And in the last century, as we developed Western medicine - modern medicine - the drug approval process started to learn how to synthesize molecules and isolate molecules from nature. So we started to step completely away from plant medicine and into a synthetic pharmaceutical landscape. The FDA fairly recently started allowing botanical drugs. So what that means is that it's full-spectrum medicines coming from the given root, shrub, leaf, flower, or mushroom. Those would be botanical drugs. So botanical drugs are not single-compound botanically derived drugs, which make up about 20% of our pharmaceuticals. They're a full-spectrum plant extract, a botanical drug from a regulatory standpoint." "So, plant-based therapeutics can mean dietary supplements that do not go through clinical trials. They're not legally prescribed by doctors and generally not covered by insurance. Whereas botanical drugs go through the FDA drug approval process, rigorous clinical trials against placebo control to become FDA approved, covered by insurance, and legally prescribable. So that's really what sets what we're doing, creating botanical drugs, apart from what people have considered plant medicine this last century." "Our most advanced drug in our pipeline is called AJA001, and it's very special to me because I've been basically working on this drug for more than 15 years. It's made in partnership with my previous company. I was the first CEO of a company called Charlotte's Web, which was really the first, and it's still the largest CBD brand out there. It was everything we learned at Charlotte's Web that kind of prompted me to start Ajna BioSciences four years ago. And that first drug is made from full-spectrum hemp, so it is CBD dominant, and it does have other cannabinoids, such as THC, as well as other minor cannabinoids. It also has certain terpenes."  #AjnaBiosciences #BotanicalMedicine #PlantBasedTherapeutics #PharmaInnovation #DrugDevelopment #NaturalMedicine #BioTech ajnabiosciences.com Listen to the podcast here

Joel Stanley is the CEO of Ajna Biosciences, a company developing the next generation of botanical medicines. These full-spectrum drugs, derived from plants and fungi, are regulated and approved through the FDA, unlike dietary supplements. Lead drug candidates are targeting autism, generalized anxiety disorder, and PTSD. With expertise in cultivating and scaling the production of botanical raw materials, Ajna is creating a sustainable model compared to wild-harvested botanicals. Joel explains, "It's no secret that before about a hundred years ago, all of our medicines were botanical medicines, or mostly coming from plants, or maybe mushrooms. And in the last century, as we developed Western medicine - modern medicine - the drug approval process started to learn how to synthesize molecules and isolate molecules from nature. So we started to step completely away from plant medicine and into a synthetic pharmaceutical landscape. The FDA fairly recently started allowing botanical drugs. So what that means is that it's full-spectrum medicines coming from the given root, shrub, leaf, flower, or mushroom. Those would be botanical drugs. So botanical drugs are not single-compound botanically derived drugs, which make up about 20% of our pharmaceuticals. They're a full-spectrum plant extract, a botanical drug from a regulatory standpoint." "So, plant-based therapeutics can mean dietary supplements that do not go through clinical trials. They're not legally prescribed by doctors and generally not covered by insurance. Whereas botanical drugs go through the FDA drug approval process, rigorous clinical trials against placebo control to become FDA approved, covered by insurance, and legally prescribable. So that's really what sets what we're doing, creating botanical drugs, apart from what people have considered plant medicine this last century." "Our most advanced drug in our pipeline is called AJA001, and it's very special to me because I've been basically working on this drug for more than 15 years. It's made in partnership with my previous company. I was the first CEO of a company called Charlotte's Web, which was really the first, and it's still the largest CBD brand out there. It was everything we learned at Charlotte's Web that kind of prompted me to start Ajna BioSciences four years ago. And that first drug is made from full-spectrum hemp, so it is CBD dominant, and it does have other cannabinoids, such as THC, as well as other minor cannabinoids. It also has certain terpenes."  #AjnaBiosciences #BotanicalMedicine #PlantBasedTherapeutics #PharmaInnovation #DrugDevelopment #NaturalMedicine #BioTech ajnabiosciences.com Download the transcript here

Dana Brown serves as President, CEO, and Chairman of the Board at iCAD Inc., which has developed a next-generation approach that leverages advancements in AI and imaging technology to improve the accuracy and efficiency of breast cancer screening.  This technology can help reduce unnecessary biopsies and additional tests while more accurately identifying cancers that need immediate attention. The concerning trend of rising breast cancer in younger women highlights the importance of early detection and personalized care plans. Dana explains, "Literally, iCAD's first FDA-cleared product in a first-generation AI was around 2002. So it's been well over 20 years. We're now on our fourth generation. So, yes, you're very accurate in describing this as a next-generation approach. So, not only has imaging technology improved over the past 20 years, but artificial intelligence has also improved. We continue to leverage the latest in artificial intelligence technology, how the artificial intelligence can be trained and learn, and a broad base of researchers that help us develop the solution. So you have new minds, new ways to think about solving the problem, and new technology that can be used to solve the problem. Then, there is a new underlying screening technology that gets better and better at clearer imaging." "The American Cancer Society reports that if we can catch a breast cancer very early in stage one, then the likelihood of, I'll say surviving breast cancer is 99%, so very, very high. So the earlier we can catch a breast cancer, the less invasive and costly and length of time the treatments can be. There are more options for those patients as well as the likelihood of a positive outcome, being able to again, have no further evidence of the disease is increased." #iCAD #BreastCancer #BreastCancerScreening #Radiology #CancerDetection #BreastBiopsies #Mammogram #WomensHealth #MedAI icadmed.com Listen to the podcast here

Dana Brown serves as President, CEO, and Chairman of the Board at iCAD Inc., which has developed a next-generation approach that leverages advancements in AI and imaging technology to improve the accuracy and efficiency of breast cancer screening.  This technology can help reduce unnecessary biopsies and additional tests while more accurately identifying cancers that need immediate attention. The concerning trend of rising breast cancer in younger women highlights the importance of early detection and personalized care plans. Dana explains, "Literally, iCAD's first FDA-cleared product in a first-generation AI was around 2002. So it's been well over 20 years. We're now on our fourth generation. So, yes, you're very accurate in describing this as a next-generation approach. So, not only has imaging technology improved over the past 20 years, but artificial intelligence has also improved. We continue to leverage the latest in artificial intelligence technology, how the artificial intelligence can be trained and learn, and a broad base of researchers that help us develop the solution. So you have new minds, new ways to think about solving the problem, and new technology that can be used to solve the problem. Then, there is a new underlying screening technology that gets better and better at clearer imaging." "The American Cancer Society reports that if we can catch a breast cancer very early in stage one, then the likelihood of, I'll say surviving breast cancer is 99%, so very, very high. So the earlier we can catch a breast cancer, the less invasive and costly and length of time the treatments can be. There are more options for those patients as well as the likelihood of a positive outcome, being able to again, have no further evidence of the disease is increased." #iCAD #BreastCancer #BreastCancerScreening #Radiology #CancerDetection #BreastBiopsies #Mammogram #WomensHealth #MedAI icadmed.com Download the transcript here